🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — August 10, 2026

The nine filings from the S&P 500 Healthcare sector on August 10, 2026, reveal a bifurcated landscape. UnitedHealth Group stands out with a powerful operational turnaround, reporting a 61% surge in net earnings and a 55% jump in operating earnings, driven by a 4.1% reduction in medical costs, signaling strong managed care execution. In stark contrast, a wave of insider selling at Thermo Fisher Scientific, Merck, and Intuitive Surgical creates a bearish undercurrent, with executives liquidating significant holdings, often via 10b5-1 plans. The sector is characterized by a divergence between a dominant managed care player showing robust financial health and a cluster of life sciences and med-tech companies where insider sentiment is cautious. Capital allocation trends are mixed, with UnitedHealth aggressively returning capital via buybacks and dividends, while others show no such activity. The primary themes are operational efficiency versus insider skepticism, making UnitedHealth a clear standout for bullish investors, while the insider sales at other names warrant close monitoring for potential headwinds.

9 high priority 9 total filings
· daily

US Earnings Financial Results SEC Filings — August 10, 2026

The 50 filings for the period ending August 10, 2026, reveal a market characterized by stark divergence: established companies like Yum China, Brookfield Asset Management, and Berkshire Hathaway are posting strong operational results and returning significant capital to shareholders, while a cluster of pre-revenue and early-stage firms (Blue Biofuels, BTC Development, Invest Green Acquisition) continue to burn cash with no clear path to profitability. A notable theme is the prevalence of 'mixed' sentiment, with many companies showing top-line growth but facing margin compression or one-time charges that obscure underlying performance. Key period-over-period trends include a surge in M&A and divestiture activity (Plains All American, Berkshire Hathaway, Lincoln International), aggressive share repurchases (Corpay, Yum China, Berkshire Hathaway), and a sharp increase in operating expenses outpacing revenue growth at several firms (Axsome Therapeutics, Lincoln International, IonQ). The most critical development is the massive, non-cash-driven net income swings at companies like IonQ and Lincoln International, which require careful analysis to separate operational reality from accounting noise. Portfolio-level patterns point to a 'barbell' market where capital is flowing to either proven cash generators or high-risk, high-reward speculative plays, with the middle ground under significant pressure.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 10, 2026

This digest of 12 SEC proxy filings reveals a bifurcated landscape: mature, cash-rich companies like Darden Restaurants are delivering record sales and consistent shareholder returns, while a cluster of smaller, cash-burning entities (Glucotrack, Peraso, Toppoint) are resorting to dilutive capital raises, reverse stock splits, and reincorporations to stay afloat. The most material event is the $6.75/share acquisition of Atai Life Sciences by Eli Lilly, offering a clear near-term cash exit with an upside CVR. The SPAC space shows a high-risk, high-reward bet with NewHold's $2.35B nuclear energy merger, where public shareholders will be heavily diluted to just 6.7% ownership. Insider trading data is sparse, but the lack of insider buying at several distressed companies is a notable bearish signal. The dominant themes are capital structure distress (3 companies seeking reverse splits or massive share increases) and governance activism (AMC's declassification and written consent proposals). The overall tone is cautious, with significant dilution risk outweighing growth catalysts in the portfolio.

12 high priority 12 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 10, 2026

The IPO pipeline on August 10, 2026, is overwhelmingly dominated by SPAC registrations, with 5 of 10 filings being blank-check companies (Inflection Point VIII, Eaglesky, JATT III, Gores Holdings XII, GigCapital10) seeking to raise a combined $320M+ in gross proceeds. This SPAC wave signals renewed sponsor confidence in the de-SPAC market, though the sector focus remains broad and largely undisclosed. Notable is the absence of traditional operating company IPOs, with only Curis Inc. (a follow-on offering) and ClearOne Inc. (an early-stage S-1) representing non-SPAC equity raises. A significant cross-current is the business combination activity from Hannon Armstrong and MN8 Energy, both filed via S-4 registration statements, indicating ongoing M&A in the energy and infrastructure sectors. The most actionable insight is the Eaglesky Acquisition Corp filing, which explicitly excludes Chinese targets despite management's China ties, creating a unique risk/reward profile. Overall, the pipeline reflects a market cautiously re-embracing SPACs while traditional IPO windows remain narrow, with no period-over-period trends available as all filings are initial registrations.

10 high priority 10 total filings
· daily

US SEC Trading Suspension Halt Orders — August 10, 2026

This digest covers five regulatory filings related to US trading suspensions, delistings, and regulatory halts, all published on August 10, 2026. The overarching theme is a wave of Nasdaq compliance challenges, with three companies (Arcadia Biosciences, Construction Partners, and Northann Corp.) receiving or triggering delisting notices due to bid price, governance, or audit committee deficiencies. Lexaria Bioscience Corp. received a high-materiality delisting notice with no disclosed reason or remediation plan, representing the highest risk. In contrast, Faraday Future Intelligent Electric Inc. (FFAI) is the sole positive outlier, having regained compliance with Nasdaq's minimum bid price rule and announcing technological breakthroughs, though it still faces stock price volatility. Period-over-period comparisons are limited as most filings lack quantitative financial data, but insider activity and governance failures (e.g., Northann's unpaid board compensation and lapsed D&O insurance) signal severe operational distress. The most critical development is the cluster of delisting risks among small-cap and micro-cap companies, which could trigger forced selling by institutional investors and liquidity crushes. Portfolio-level patterns indicate a sector-wide struggle for small-cap biotech and EV companies to maintain listing standards, with reverse stock splits and governance fixes as common but uncertain remedies.

5 high priority 5 total filings
· daily

US Executive Officer Management Changes SEC — August 10, 2026

The August 10, 2026, filings reveal a significant wave of leadership transitions across US equities, with 37 filings covering executive and director changes. A key theme is the prevalence of planned and orderly successions, particularly in the energy and industrial sectors (e.g., Diversified Energy, U. S. Premium Beef, Infinity Natural Resources), which contrasts with a few sudden departures that raise governance flags (e.g., Diversified Energy CEO, Lincoln National CFO). Notable appointments include high-caliber executives from aerospace, fintech, and biotech, signaling strategic pivots toward growth and innovation. Insider activity is sparse, but the positive sentiment around new board members at Duolingo, Annexon, and Applied Aerospace suggests strong governance enhancements. Capital allocation trends are mixed, with Mueller Industries maintaining a steady dividend, while other companies focus on executive compensation adjustments. The overall market implication is a period of strategic repositioning, with investors advised to monitor the quality of succession planning and the experience of incoming leadership as key indicators of future performance.

37 high priority 37 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 10, 2026

The August 10, 2026 batch of 37 board and officer change filings reveals a high volume of leadership transitions, with a mix of planned successions, sudden departures, and strategic appointments. Notable trends include a wave of CFO transitions (Lincoln National, Infinity Natural Resources, NIKE, MicroVision), several board appointments bringing deep industry expertise (Atmos Energy, SAIC, Southwest Airlines, Duolingo, Werner), and a few high-risk sudden departures (Diversified Energy CEO, JOCOM Holdings overhaul). While most changes are routine, the lack of detail in several filings (e.g., Commercial Vehicle Group, ACV Auctions) and the sudden, unexplained CEO departure at Diversified Energy warrant caution. Positive sentiment dominates in filings with clear succession plans (U.S. Premium Beef, Owens & Minor), while the market should watch for potential instability at Diversified Energy and the strategic implications of new leadership at JOCOM and FingerMotion. No major period-over-period financial trends are available, but the concentration of CFO changes and the appointment of directors with strong capital markets experience suggest a focus on financial discipline and strategic growth.

37 high priority 37 total filings
· daily

USA Insider Trading Pulse — August 10, 2026

The August 10, 2026, insider trading pulse reveals a bifurcated market with strong insider conviction in select technology and financial names, contrasted by significant insider selling and option exercises in consumer and industrial sectors. The most critical development is the massive $13.6M sale by Floor & Decor's Executive Chair, which, despite being part of a planned exercise-and-sale, signals a potential top in the home improvement cycle. Conversely, a coordinated wave of small-scale insider buying across 10 executives at Taiwan Semiconductor (TSMC) provides a powerful, albeit symbolic, vote of confidence in the semiconductor leader. The data shows a clear pattern of insider buying in undervalued financials (Origin Bancorp, Bankwell) and beaten-down growth stories (PROCEPT BioRobotics, 51Talk), while insider selling is concentrated in companies with recent stock strength (Karooooo, InterDigital). The overall sentiment is mixed, with a slight bullish tilt from the number of buying transactions, but the sheer dollar volume of selling from top executives at Floor & Decor and Karooooo warrants caution.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 10, 2026

The August 10, 2026 M&A filing batch reveals a bifurcated SPAC market: while new IPOs (Pinnacle, East West Ave) continue to raise capital at $10/unit, the high-profile Yorkville-Crypto.com-TMTG deal collapsed, signaling waning SPAC appetite for complex transactions. Strategic acquisitions dominate, led by Amneal's transformative Kashiv BioSciences deal (biosimilars), Onto Innovation's $720M minority stake in Rigaku (semiconductor X-ray), and Ondas' Cyberhawk acquisition (drone inspection). Notable trends include a shift toward minority stakes and asset purchases with earn-outs (Byrna), reflecting disciplined capital deployment. Insider activity is limited, but sponsor ownership in East West Ave (15.12%) signals alignment. Forward-looking catalysts include Amneal's biosimilar launch cadence and Pinnacle's target search. Risks center on dilution (Ondas), deal termination fallout (Yorkville), and SPAC execution uncertainty (Dune, Quetta).

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 10, 2026

Overnight filings reveal a bifurcated market with strong growth in energy services and semiconductors contrasting with consumer and healthcare margin pressures. National Energy Services Reunited (NESR) posted record revenue (+59% YoY) and a 190% net income surge, while semiconductor firms ASE Technology and ChipMOS reported robust 43%+ YoY revenue growth. However, consumer-facing companies like AirSculpt Technologies (-3% revenue) and Dole plc (-14.8% Adj. EBITDA) face headwinds from input cost inflation. A notable capital allocation theme emerged: Yum China repurchased $530M in shares (6.7% share count reduction), while Berkshire Hathaway spent $4.5B on buybacks but saw cash drop 63% YoY due to $9.7B in acquisitions. The SPAC market showed renewed activity with two new IPOs (Eaglesky Acquisition Corp and Inflection Point Acquisition Corp VIII), signaling potential thawing. Insider trading data was sparse, but the delayed Q2 report from Beasley Broadcast Group due to debt restructuring tax accounting raises governance concerns. Overall, the data suggests rotating toward industrials/energy and away from consumer discretionary, while monitoring cash burn rates at pre-revenue companies like Blue Biofuels (cash down 66% to $22K).

9 high priority 41 medium 50 total filings
· daily

VA Healthcare & Services Contracts — August 09, 2026

This digest covers a single, large civilian contract from the Department of Veterans Affairs (VA) valued at $209.2 million, awarded to QTC Medical Services Inc., a subsidiary of Leidos Holdings, Inc. The contract, for medical disability examinations in the Southeast region, is a firm-fixed-price delivery order with a one-year performance period that has been nearly fully executed ($196.6M outlayed). While the award demonstrates Leidos' established position in the VA medical evaluation market, the neutral signal and lack of forward-looking growth visibility due to the short-term, completed nature of the contract limit bullish conviction. Key risks include the absence of a clear follow-on award and the fixed-price structure, which caps upside. The primary watch item is Leidos' ability to secure subsequent VA contracts in this or other regions to sustain this revenue stream.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — August 09, 2026

This digest covers a single, massive $626.5 million firm-fixed-price contract awarded to SIGA TECHNOLOGIES, INC. by the Department of Health and Human Services (HHS) / BARDA for late-stage development and procurement of a smallpox antiviral drug. The contract is entirely civilian (biodefense), not defense-related, and $447.2 million has already been outlayed, signaling strong government commitment. The highest-conviction signal is the long-term revenue visibility through 2029, though the fixed-price structure introduces execution risk if development costs exceed estimates. Key watch items include potential contract modifications and SIGA's cost performance relative to the fixed-price ceiling.

1 total filings
· daily

New Federal Contractors — August 09, 2026

The three contracts total $993.8 million, with one-third defense-related (the VA award to QTC Medical Services/Leidos) and the remainder civilian HHS awards. The dominant theme is biodefense and health services: SIGA Technologies' $626.5 million smallpox antiviral contract from HHS/BARDA is the highest-conviction signal, offering long-term revenue visibility through 2029 under a fixed-price structure. However, execution risk is medium given the fixed-price nature, and the contract's full-and-open competition suggests potential future competition. The VA medical exam contract for Leidos is a completed, one-year award with no forward growth visibility, while the OUR RESCUE legal services contract carries high pricing risk due to its time-and-materials structure and short base period. Key watch items include SIGA's cost performance and option exercises, and HHS's decision on OUR RESCUE's options by February 2027.

3 total filings
· daily

Significant Contract Modifications ($10M+) — August 09, 2026

The four contract modifications analyzed for August 9, 2026, total $994.8 million, with a clear civilian tilt (3 of 4 contracts, $993.8 million) versus defense (1 contract, $1.0 million). The dominant theme is HHS BARDA's biodefense preparedness, led by a $626.5 million firm-fixed-price award to SIGA TECHNOLOGIES for smallpox antiviral development—the highest-conviction signal due to its multi-year revenue visibility and strong government commitment. A key risk is the $158.1 million non-competed, time-and-materials bridge contract to OUR RESCUE for HHS legal services, which carries high execution risk and limited competitive visibility. The VA's $209.2 million medical disability exam award to QTC MEDICAL SERVICES (Leidos) is a completed contract, offering no forward growth signal. Lockheed Martin's $1.0 million NASA R&D contract is immaterial to its revenue base.

4 total filings
· daily

Contract Deobligations Alert — August 09, 2026

This digest covers $994.8 million in total obligations across four contracts, with two defense-related awards (VA and NASA) and two civilian HHS awards. The dominant theme is civilian biodefense and medical services, led by a $626.5 million SIGA Technologies contract from HHS/BARDA for smallpox antiviral development—the highest-conviction signal. A $209.2 million Leidos subsidiary (QTC Medical Services) VA contract is near-complete, limiting forward visibility. Key risks include execution risk on SIGA's fixed-price structure and the non-competed, high-risk $158.1 million HHS legal services award to nonprofit OUR RESCUE. Investors should watch SIGA's cost performance and option exercises on the OUR RESCUE bridge contract.

4 total filings
· daily

Contract Option Exercises — August 09, 2026

The August 9, 2026 contract option exercise stream totals $994.8 million across four awards, with a 2/4 defense-related split (QTC Medical Services for the VA and Lockheed Martin for NASA), while the largest award is a $626.5 million HHS/BARDA contract to SIGA Technologies for smallpox antiviral development, representing the highest-conviction signal. The dominant theme is civilian biodefense and healthcare services, driven by SIGA and OUR RESCUE, with defense-related spending limited to VA medical exams and a small NASA R&D award. The strongest signal is SIGA's multi-year fixed-price contract, offering long-term revenue visibility, but the neutral signals from QTC and OUR RESCUE highlight execution and competition risks. Key watch items include option exercises for OUR RESCUE's bridge contract and potential follow-on VA awards for Leidos.

4 total filings
· daily

All HHS Contracts — August 09, 2026

The two HHS contracts totaling $784.6 million reveal a dominant biodefense theme, with SIGA TECHNOLOGIES' $626.5 million smallpox antiviral award accounting for 80% of total obligation and representing the highest-conviction signal. The civilian agency focus is clear, though one contract is defense-related via BARDA's biodefense mission. The SIGA contract provides multi-year revenue visibility through 2029 under a fixed-price structure, while the OUR RESCUE $158.1 million legal services bridge contract carries execution risk due to its non-competed, time-and-materials structure and short 6-month base period. Key risks include SIGA's fixed-price execution risk and OUR RESCUE's option exercise dependency before February 2027.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — August 09, 2026

The three contracts tracked on August 9, 2026, total $993.8 million, with a 1:2 defense-to-civilian split. The dominant theme is HHS biodefense and legal services spending, accounting for 78.9% of total value. The highest-conviction signal is SIGA Technologies' $626.5 million firm-fixed-price contract for smallpox antiviral development, which provides multi-year revenue visibility through 2029. A key risk is that the $158.1 million OUR RESCUE bridge contract is non-competed and time-and-materials, carrying execution and pricing uncertainty. Investors should watch for option exercises on the OUR RESCUE contract and any follow-on VA medical exam awards for Leidos.

3 total filings
· daily

High-Value Federal Grants ($5M+) — August 09, 2026

This digest covers three high-value federal grants totaling $993.8 million, with a civilian-heavy split (2 of 3 contracts from HHS, 1 from VA) and only one defense-related award. The dominant theme is biodefense and health services, led by a $626.5 million HHS/BARDA contract to SIGA TECHNOLOGIES for smallpox antiviral development—the highest-conviction bullish signal due to its long-term fixed-price structure and $447.2 million already outlayed. However, a $158.1 million non-competed HHS legal services bridge contract to nonprofit OUR RESCUE introduces execution risk given its time-and-materials pricing and short base period. Key watch items include SIGA's cost performance on fixed-price terms and option exercises for OUR RESCUE by February 2027.

3 total filings
· daily

General Federal Contracts — August 09, 2026

The August 2026 federal contract stream totals $993.8 million across three awards, with a civilian-heavy split (2/3 HHS, 1/3 VA) and no direct DOD contracts. The dominant theme is biodefense and health services, led by SIGA Technologies' $626.5 million HHS/BARDA contract for smallpox antiviral development—the highest-conviction signal, offering multi-year revenue visibility through 2029. QTC Medical Services (Leidos subsidiary) secured a $209.2 million VA delivery order, now largely executed, while OUR RESCUE received a $158.1 million HHS legal services bridge contract with high execution risk. Key watch items: SIGA's fixed-price execution risk and OUR RESCUE's option exercise decision by February 2027.

3 total filings